Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to evaluate the long term safety and tolerability of repeated administration of subcutaneous (sc) CEP 33457 every 4 weeks over 72 weeks in patients with systemic lupus erythematosus (SLE) who have participated in a previous Cephalon sponsored clinical study of CEP-33457. Safety will be assessed by evaluating the following: •occurrence of adverse events •clinical laboratory tests (serum chemistry, hematology, and urinalysis) •vital signs (blood pressures, pulse, temperature, and body weight) measurements •12 lead ECG •physical examination findings, including physical examination symptom directed findings •concomitant medication usage
Critère d'inclusion
- Patients with Systemic Lupus Erythematosus (SLE)